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Abstract To study functional aspects of the exon 1 encoded
region of the human immunodeficiency virus type 1 Rev protein,
the viral Tev protein which exhibits low Rev activity but lacks the
rev exon 1 encoded region was examined. Neither Rev^Tev
heteromer complex formation nor inhibition of Rev by an export
deficient Tev mutant was observed. Insertion of the rev exon 1
encoded region into the Tev mutant allowed it to oligomerize with
Rev and act as a trans-dominant negative mutant. This showed
that the exon 1 encoded region of Rev is essential for
oligomerization and that oligomerization is a prerequisite for
trans-dominant inhibition. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The regulatory proteins of the human immunode¢ciency
virus type 1 (HIV-1) Tat and Rev are required for HIV
gene expression and virus replication. The Tat protein stim-
ulates and increases transcriptional elongation by binding to
an RNA sequence located in the promoter region, long termi-
nal repeat (LTR) [1,2]. The Tat protein is encoded by two
exons, the ¢rst preceding the env gene and the second within
the env gene. The rev gene consists of two exons partly over-
lapping the tat exons using di¡erent reading frames. The
mRNAs encoding Tat and Rev are obtained by complete
splicing of the viral pre-mRNA. The Rev protein promotes
cytoplasmic expression of unspliced and incompletely spliced
HIV-1 mRNAs encoding the structural HIV components [3^
6]. Two functional domains necessary for function are encom-
passed within the exon 2 encoded region of Rev. The basic
domain (amino acids (aa) 35^50) is responsible for the nuclear
and nucleolar localization of Rev as well as speci¢c binding of
Rev to the RNA target sequence, Rev responsive element
(RRE) [7^15]. The other essential domain (aa 75^83), called
nuclear export signal (NES), signals active nuclear export of
Rev [16^19]. Mutations of essential amino acids within this
domain generate trans-dominant negative mutants [20^25]. It
has been assumed that trans-dominant inhibition is caused by
formation of mixed multimers consisting of wild type and
mutant Rev [17,24,26]. Oligomerization appears to be critical
for Rev function and studies of Rev mutants have indicated
several amino acid residues encoded by exon 1 to be essential
in this respect [24,27,28]. However, other studies have shown
that additional regions of the molecule may be implicated
[8,13,15,29,30]. The Tev protein, also called Tnv, is encoded
by an alternatively spliced viral mRNA containing the sequen-
ces from tat exon 1, an internal env exon and rev exon 2 [31^
33]. Accordingly, essential domains of both Tat and Rev are
encompassed within the Tev protein. The Tat activity of Tev
is similar to that of Tat, but the Rev activity has been found
to be lower than that of wild type Rev [31,33].
The exon 1 encoded part of Rev is not present within the
Tev protein. This provided the unique opportunity to examine
its importance in mediating oligomer formation by inserting it
into Tev. In addition, it allows one to investigate if complex
formation is obligatory for trans-dominant inhibition. There-
fore, the exploitation of the viral protein Tev instead of Rev
mutants was an alternative strategy to analyze the function of
the exon 1 encoded part of Rev.
2. Materials and methods
2.1. Plasmids
Plasmids encoding Tat and wild type/mutant Rev were kindly pro-
vided by M. Malim and B. Cullen [20,23]. The Rev mutant previously
called v18/23 is here referred to as RevvNES. The plasmid
pcDNA1E7 containing the cytomegalo virus immediate early pro-
moter and HIV-1/XHB2 rev, env, nef and 3P LTR sequences, was a
gift from J. Sodroski and R. Wyatt. The rev negative reporter plasmid
pSVc21B containing the complete HIV sequence with a mutation in
the rev gene was previously described [34]. The plasmid pNL1,4,6D7
encoding the tev cDNA sequence was generously provided by B.
Felber [31]. The tat cDNA in pctat was replaced by the tev cDNA
using £anking SalI and XhoI sites. The resulting plasmid was named
pctev. The plasmid pctevvNES was generated by combining the rele-
vant parts of pctev and pcrevvNES using the unique PstI and BamHI
restriction sites. Insertion of rev exon 1 into the tev cDNA between
the env exon and rev exon 2 was accomplished by a two step PCR
approach. A fragment containing tat exon 1 and the env exon of tev
was ampli¢ed from the pctev plasmid while the other fragment was
ampli¢ed from the pcrev plasmid. The two fragments were ligated and
the resulting 985 bp fragment £anked by the SalI and XhoI sites was
cloned into the precut pctat vector. The vector was called pctevNrev
and the expressed protein was called TevNRev. The pctevNrevvNES
vector was made by the same procedure as pctevvNES. An overview
of the di¡erent wild type and mutant proteins is shown in Fig. 1.
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2.2. Cell lines and transfections
Chinese hamster ovary (CHO) cells or COS-7 cells were seeded into
35 mm wells 1 day prior to transfection, grown to 60^70% con£uence
and transfected by the lipofectamine procedure of Gibco BLR using
5 Wl lipofectamine per 35 mm well. The amount of plasmid per well
varied from 50 to 200 ng for pSVc21B, 1^2 Wg for the tev and rev
plasmids and 500 ng pcDNA1E7.
2.3. Monoclonal antibodies (MAbs) and immuno£uorescence analysis
The anti-Rev MAb 8E7 (IgG2a) and the anti-Tat MAb 1D9 (IgG1)
also recognizing the Tev protein have been described [35,36]. The
MAb 8E7 did not recognize the vNES mutants. The MAb binding
epitopes are schematically outlined in Fig. 1. For detection of gp160/
120 (Env) the anti-gp120 MAb ADP327 (IgG1) supplied by H.C.
Holmes was used [37]. The immuno£uorescence assays were per-
formed as previously described using goat isotype speci¢c secondary
antibodies conjugated with FITC or Texas red (Southern Biotechni-
cal) [17].
2.4. Western blot analysis
COS cells in 35 mm wells were collected in 150 Wl of lysis bu¡er (10
mM Tris^HCl pH 7.4, 10 mM NaCl, 1.5 mM MgCl2 and 0.5% NP40)
48 h after transfection. The samples were analyzed by Western blot
using the ECL detection system (Amersham) as previously described
[17]. Pre-stained molecular weight standards (Bio-Rad) and a re-
combinant Rev protein (Intracel) were included in the experiments.
3. Results
3.1. Comparison of Rev, Tev and TevNRev
Immuno£uorescence analysis of CHO and COS cells trans-
fected with the di¡erent rev and tev containing plasmids dem-
onstrated a similar intra-cellular distribution of the Rev, Tev
and TevNRev proteins localizing to the nucleoli, nucleoplasm
and the cytoplasm (not shown). As the RevvNES protein,
also the TevvNES and TevNRevvNES localized to the nu-
cleus with extensive nucleolar accumulation (not shown). The
Rev activity of Tev was reported either to be low or undetect-
able [31,33]. In this study, however, the Rev activity of Tev
was easily assessed using the rev negative provirus construct.
Cells transfected with pcrev and pctevNrev produced a similar
amount of the Env proteins, whereas less was produced in
cells transfected with pctev (Fig. 2A, lanes 1^3). Comparable
amounts of Rev, Tev and TevNRev were expressed in the cells
co-transfected with pSVc21B and pcrev, pctev or pctevNrev,
respectively (Fig. 2B, lanes 1^3).
3.2. Oligomerization between M6 and vNES mutants
The observed low Rev activity of the Tev protein may be
caused by its inability to oligomerize. In order to test this
assumption, an in vivo oligomerization assay was used. The
assay employs co-expression of the nuclear import defective
Rev mutant M6 and other Rev mutants comprising an intact
nucleolar localization signal. Oligomerization between M6
and these mutants is then demonstrated by nucleolar import
of M6 [27]. In cells expressing M6 only, the mutant was lo-
calized to the cytoplasm with a di¡use nucleoplasmic staining
Fig. 1. The Rev and Tev wild type and mutant proteins schemati-
cally outlined. The epitopes of the MAbs 8E7 and 1D9 are indi-
cated. The drawings are not to scale.
Fig. 2. Rev function of wild type Rev, Tev and TevNRev. Western
blot analysis of lysates from COS cells co-transfected with the rev3
proviral construct pSVc21B together with pcrev (lanes 1), pctev
(lanes 2) and pctevNrev (lanes 3). A: The samples were separated
on a 7.5% SDS^PAGE. Detection of gp160/120 by the anti-gp120
MAb ADP327. B: The same samples as in A were separated by
15% SDS^PAGE. The anti-Rev MAb 8E7 was used as primary
antibody. Recombinant Rev (25 ng) was applied in the lane to the
left. The migration of Rev, Tev and TevNRev proteins is indicated
to the right.
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in some cells always excluding the nucleoli (Fig. 3A). To ex-
amine if oligomerization between the Tev and Rev proteins
takes place, the M6 plasmid was co-transfected into CHO
cells together with pctevvNES or the control plasmid
pcrevvNES. As previously described, co-expression of Re-
vvNES with M6 directed M6 to the nucleoli and the nucleo-
plasm (Fig. 3B). Co-expression of M6 with TevvNES did not
change the cytoplasmic localization pattern of M6. TevvNES
was detected in the nucleoli and the nucleoplasm while M6
localized to the cytoplasm in the same cells (Fig. 3C^F). Ac-
cordingly, no interaction between M6 and TevvNES had oc-
curred. However, nucleolar localization of M6 was observed
when expressing TevNRevvNES with M6 though less e⁄cient
as when RevvNES was used. This was re£ected in the number
of transfected cells with nucleolar localization of M6 and the
remains of cytoplasmic M6 in the same cells (Fig. 3G^J).
3.3. Trans-dominant inhibition of Rev by vNES mutants
A large amount of Env proteins and very little of the Rev
protein are expressed from the vector pcDNA1E7 (containing
the HIV rev and env genes). It was previously shown that co-
expressed RevvNES reduced the amount of Env proteins.
Concurrently, the amount of Rev protein increased showing
that inhibition of Rev leads to enhanced splicing of the pre-
mRNA [38]. Accordingly, increase of the Rev protein encoded
by spliced mRNA enabled an assessment of the bona ¢de
trans-dominant inhibitory e¡ect distinguishing it from toxic
e¡ects or a competition between wild type and mutant Rev
for target RNA which may also inhibit the expression of
gp160/120 (Env). This assay was used to examine if TevvNES
executed a trans-dominant negative e¡ect when co-expressed
with Rev. For comparison, cells co-transfected with
pcDNA1E7 and prevvNES were included. There was a clear
inhibition of expressed Env protein (gp160/120) by RevvNES
(Fig. 4A, lanes 1 and 2). Concurrently, more Rev was pro-
duced (Fig. 4B, lanes 1 and 2). There was, however, neither
decrease of gp160/120 (Fig. 4A, lane 4) nor increase of Rev
(Fig. 4B, lane 4) by co-expressed TevvNES. No signi¢cant
Fig. 3. In vivo oligomerization assay. Immuno£uorescence analysis of the Rev mutant M6 expressed alone or together with the di¡erent vNES
mutants in CHO cells. M6 is detected by the anti-Rev MAb 8E7 combined with Texas red labeled anti-mouse IgG2a, while TevvNES and
TevNRevvNES are detected by the anti-Tat MAb 1D9 combined with FITC-labeled anti-mouse IgG1. A: M6 localizes to cytoplasm in ex-
pressing cells. B: M6 localizes to the nucleus and nucleoli when co-expressed with RevvNES (not recognized by MAb 8E7). C and D, E and
F: Double labeling of M6 and co-expressed TevvNES. M6 localizes to the cytoplasm while TevvNES localizes to the nucleus and nucleolus in
the same cells. G and H, I and J: Double labeling of M6 and co-expressed TevNRevvNES. M6 localizes to the cytoplasm, nucleus and nucleo-
li in cells co-expressing TevNRevvNES which is exclusively in the nucleus.
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inhibition of gp160/120 production was demonstrated by co-
transfection with pctev (Fig. 4A,B, lanes 3). On the other
hand, Western blot analysis of COS cells co-transfected with
pcDNA1E7 and pctevNrevvNES showed that also the ability
to trans-dominantly inhibit Rev was achieved by the insertion
of the rev exon 1 encoded part into the Tev mutant (Fig.
4C,D). The inhibition was demonstrated as downregulation
of Env proteins with an accompanied increase of wild type
Rev (Fig. 4C,D, comparing lanes 1 and 3). This experiment
also included control cells co-transfected with RevvNES for
comparing the e¡ect of the two vNES mutants (Fig. 4C,D,
lanes 2).
4. Discussion
In this study functional properties of the exon 1 encoded
region of Rev were examined by comparing the activities of
the natural viral protein Tev lacking the rev exon 1 encoded
region with an arti¢cial Tev protein where the missing Rev
region was inserted (Fig. 1). The Rev activity of wild type Tev
was, according to previous studies, found to be lower than
that of Rev [31], while the activities of TevNRev and Rev
were similar (Fig. 2). It should be kept in mind that the
amount of viral pre-mRNA available for Rev regulation in
the cells expressing the two Tev proteins may have been high-
er than in the cells co-transfected with pcrev since transcrip-
tion from the LTR promoter is enhanced by Tat and Tev [31].
There was, however, a clear di¡erence in Env expression when
comparing the cells transfected with pctev and pctevNrev sug-
gesting an increase in the Rev activity caused by the exon 1
encoded region present in TevNRev.
It was found that the export de¢cient Tev protein neither
oligomerized with Rev M6 nor trans-dominantly inhibited
Rev. Both these functions were gained by inserting the exon
1 encoded part into the Tev mutant. The inhibition of TevN-
RevvNES was not as e⁄cient as the inhibition by RevvNES
(Fig. 4C,D, comparing lanes 2 and 3). Also, the nuclear im-
port of M6 by co-expressed TevNRevvNES was not as con-
spicuous as when RevvNES was co-expressed (Fig. 3). The
observed di¡erences in activity may be caused by an impaired
folding of the exon 1 encoded region of TevNRev. It was not
possible to ensure correct folding of the Rev moiety other
than to consider the observed antibody recognition and the
rise in Rev activity that both are indications of native con-
formation. Nevertheless, the results demonstrated a correla-
tion between the ability of vNES mutants to trans-dominantly
Fig. 4. Inhibition of the Rev activity by vNES mutants. Western blot analysis of lysates from COS cells co-transfected with pcDNA1E7 and
the plasmids indicated above the lanes. The samples were separated on 7.5% SDS^PAGE (A and C) for detection of gp160/120 by the anti-
gp120 MAb ADP327 or 15% SDS^PAGE (B and D) for detection of Rev by MAb 8E7. A: Lane 1, gp160/120 expressed from pcDNA1E7 en-
coding rev and env. Lane 2, inhibition of gp160/120 production by co-expressed RevvNES. Lane 3, little e¡ect of co-expressed Tev. Lane 4, no
inhibition by co-expressed TevvNES. B: Rev expression in the same samples as in A. Lane 1, Rev expressed from pcDNA1E7. Lane 2, in-
crease of Rev caused by co-expressed RevvNES. Lane 3, detection of co-expressed Tev, no increase of Rev. Lane 4, no increase of Rev by co-
expressed TevvNES. C and D: The inhibitory e¡ect of TevNRevvNES compared to that of RevvNES. The trans-dominant inhibitory e¡ect of
TevNRevvNES is shown as decrease of gp160/120 (comparing lanes 1 and 3 in C) and increase of Rev (comparing lanes 1 and 3 in D).
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inhibit Rev function and the ability of such mutants to oligo-
merize with Rev. These experiments therefore con¢rmed the
previous mutation studies suggesting that it is the exon 1
encoded N-terminal region that mediates oligomerization of
Rev molecules [24,27,39]. Furthermore, it was shown that
heteromeric complex formation indeed is required for the
trans-dominant negative inhibition of Rev by vNES mutants.
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